MX2011011229A - Metodo para reducir la presion intraocular en los seres humanos. - Google Patents

Metodo para reducir la presion intraocular en los seres humanos.

Info

Publication number
MX2011011229A
MX2011011229A MX2011011229A MX2011011229A MX2011011229A MX 2011011229 A MX2011011229 A MX 2011011229A MX 2011011229 A MX2011011229 A MX 2011011229A MX 2011011229 A MX2011011229 A MX 2011011229A MX 2011011229 A MX2011011229 A MX 2011011229A
Authority
MX
Mexico
Prior art keywords
intraocular pressure
humans
reducing intraocular
formula
compounds
Prior art date
Application number
MX2011011229A
Other languages
English (en)
Spanish (es)
Inventor
Shikha Barman
Rudolf A Baumgartner
Original Assignee
Inotek Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43030847&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011011229(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inotek Pharmaceuticals Corp filed Critical Inotek Pharmaceuticals Corp
Publication of MX2011011229A publication Critical patent/MX2011011229A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Prostheses (AREA)
MX2011011229A 2009-05-01 2010-04-30 Metodo para reducir la presion intraocular en los seres humanos. MX2011011229A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17465509P 2009-05-01 2009-05-01
US21999009P 2009-06-24 2009-06-24
PCT/US2010/033112 WO2010127210A1 (en) 2009-05-01 2010-04-30 Method of reducing intraocular pressure in humans

Publications (1)

Publication Number Publication Date
MX2011011229A true MX2011011229A (es) 2011-11-18

Family

ID=43030847

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011229A MX2011011229A (es) 2009-05-01 2010-04-30 Metodo para reducir la presion intraocular en los seres humanos.

Country Status (25)

Country Link
US (2) US8470800B2 (enExample)
EP (1) EP2424546B1 (enExample)
JP (1) JP5778663B2 (enExample)
KR (1) KR101757940B1 (enExample)
CN (1) CN102413832B (enExample)
AU (1) AU2010242943B2 (enExample)
BR (1) BRPI1009971A2 (enExample)
CA (1) CA2762064A1 (enExample)
CL (1) CL2011002675A1 (enExample)
DK (1) DK2424546T3 (enExample)
EA (1) EA024042B1 (enExample)
ES (1) ES2554684T3 (enExample)
HR (1) HRP20151200T1 (enExample)
HU (1) HUE028068T2 (enExample)
IL (1) IL216081A (enExample)
MX (1) MX2011011229A (enExample)
MY (1) MY159244A (enExample)
NZ (1) NZ596428A (enExample)
PL (1) PL2424546T3 (enExample)
PT (1) PT2424546E (enExample)
RS (1) RS54378B1 (enExample)
SG (1) SG175346A1 (enExample)
SI (1) SI2424546T1 (enExample)
SM (1) SMT201500295B (enExample)
WO (1) WO2010127210A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008062567A1 (de) 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Dipeptoid-Prodrugs und ihre Verwendung
DE102009006602A1 (de) * 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
CA2774704A1 (en) * 2009-10-26 2011-05-05 Inotek Pharmaceuticals Corporation Ophthalmic formulation and method of manufacture thereof
EA025415B1 (ru) * 2010-01-11 2016-12-30 Инотек Фармасьютикалз Корпорейшн Комбинация, набор и способ снижения внутриглазного давления
PT2555775T (pt) * 2010-03-19 2017-02-01 Inotek Pharmaceuticals Corp Composições de combinação de agonistas de adenosina a1 e inibidores de anidrase carbónica para redução da pressão intra-ocular
LT2555776T (lt) * 2010-03-19 2017-04-25 Inotek Pharmaceuticals Corporation Adenozino a1 agonistų ir neselektyvių beta adrenerginių receptorių blokatorių derinio kompozicijos, skirtos akispūdžio mažinimui
EP2569325A4 (en) 2010-03-26 2013-10-09 Inotek Pharmaceuticals Corp METHOD FOR REDUCING INNER EYE PRESSURE IN HUMANS USING N6-CYCLOPENTYLADENOSINE (CPA), CPA DERIVATIVES OR PRODRUGS THEREOF
DE102010030688A1 (de) 2010-06-30 2012-01-05 Bayer Schering Pharma Aktiengesellschaft Substituierte Dicyanopyridine und ihre Verwendung
US20120058983A1 (en) * 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
US9278991B2 (en) * 2012-01-26 2016-03-08 Inotek Pharmaceuticals Corporation Anhydrous polymorphs of [(2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)} methyl nitrate and processes of preparation thereof
CA2903114A1 (en) 2013-03-15 2014-09-25 Inotek Pharmaceuticals Corporation Ophthalmic formulations
EP3247715A1 (en) * 2014-12-03 2017-11-29 Inotek Pharmaceuticals Corporation Methods of preventing, reducing or treating macular degeneration

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101010085B (zh) 2004-05-26 2012-12-26 伊诺泰克制药公司 嘌呤衍生物作为腺苷a1受体激动剂及其用法
DE602005020286D1 (de) * 2004-05-26 2010-05-12 Inotek Pharmaceuticals Corp Purinderivate als adenosin a 1 rezeptoragonisten und anwendungsverfahren dafür
AU2006320578B2 (en) * 2005-11-30 2013-01-31 Inotek Pharmaceuticals Corporation Purine derivatives and methods of use thereof
CA2774704A1 (en) * 2009-10-26 2011-05-05 Inotek Pharmaceuticals Corporation Ophthalmic formulation and method of manufacture thereof
EA025415B1 (ru) * 2010-01-11 2016-12-30 Инотек Фармасьютикалз Корпорейшн Комбинация, набор и способ снижения внутриглазного давления
PT2555775T (pt) * 2010-03-19 2017-02-01 Inotek Pharmaceuticals Corp Composições de combinação de agonistas de adenosina a1 e inibidores de anidrase carbónica para redução da pressão intra-ocular
LT2555776T (lt) * 2010-03-19 2017-04-25 Inotek Pharmaceuticals Corporation Adenozino a1 agonistų ir neselektyvių beta adrenerginių receptorių blokatorių derinio kompozicijos, skirtos akispūdžio mažinimui

Also Published As

Publication number Publication date
HK1167599A1 (en) 2012-12-07
ES2554684T3 (es) 2015-12-22
HRP20151200T1 (hr) 2016-01-15
CL2011002675A1 (es) 2012-06-01
KR101757940B1 (ko) 2017-07-13
KR20120017026A (ko) 2012-02-27
IL216081A (en) 2015-11-30
WO2010127210A1 (en) 2010-11-04
EA024042B1 (ru) 2016-08-31
US8470800B2 (en) 2013-06-25
EA201171339A1 (ru) 2012-05-30
EP2424546A4 (en) 2013-01-23
IL216081A0 (en) 2012-01-31
SMT201500295B (it) 2016-01-08
SI2424546T1 (sl) 2016-02-29
PL2424546T3 (pl) 2016-04-29
CN102413832B (zh) 2015-11-25
JP5778663B2 (ja) 2015-09-16
PT2424546E (pt) 2015-12-23
US20100279970A1 (en) 2010-11-04
EP2424546B1 (en) 2015-10-28
BRPI1009971A2 (pt) 2016-03-15
NZ596428A (en) 2014-03-28
US20130217643A1 (en) 2013-08-22
HUE028068T2 (en) 2016-11-28
EP2424546A1 (en) 2012-03-07
MY159244A (en) 2016-12-30
CN102413832A (zh) 2012-04-11
SG175346A1 (en) 2011-11-28
AU2010242943B2 (en) 2016-09-29
AU2010242943A1 (en) 2011-12-01
JP2012525437A (ja) 2012-10-22
RS54378B1 (sr) 2016-04-28
CA2762064A1 (en) 2010-11-04
DK2424546T3 (en) 2015-12-14

Similar Documents

Publication Publication Date Title
MX2011011229A (es) Metodo para reducir la presion intraocular en los seres humanos.
MX2011011094A (es) Derivados de prolina como inhibidores de catepsina.
EA201300860A1 (ru) Кристаллические трипептидные ингибиторы эпоксикетон-протеазы
NZ597517A (en) 5-fluoropyrimidinone derivatives
MY164731A (en) Compound
MX336381B (es) Boronatos como inhibidores de arginasa.
MX358679B (es) Derivado de anillo de heteroarilo de seis miembros de pirrol, método de preparación del mismo y usos médicos del mismo.
UA104885C2 (uk) Ізотіазолілоксифеніламідини та їх застосування як фунгіцидів
PH12015501494A1 (en) Method for producing substituted 5-fluoro-1h-pyrazolopyrimidines
MX2011011733A (es) Inhiibidores de dihidroorotato deshidrogenasa como compuestos virostaticos.
MX2012004780A (es) Inhibidores de akt.
UA111628C2 (uk) Композиція для боротьби з хворобою рослини та її застосування
NZ607149A (en) Galacto-oligosaccharide-containing composition and a method of producing it
PH12014500179A1 (en) Fixed dose combination of bimatoprost and brimonidine
NZ597570A (en) N1-acyl-5-fluoropyrimidinone derivatives
PH12013500554A1 (en) Process for preparing pan-cdk inhibitors of the formula (i) and intermediates in the preparation
UA107666C2 (uk) Застосування l-серину як лікарського засобу для попередження та/або лікування свербіжу шкіри
MX349373B (es) Nuevos derivados de pirazina.
PT2462098E (pt) Processos para a preparação de derivados de ácido 1-(2- halobifenil-4-il)-ciclopropanocarboxílico
GEP20156244B (en) New tertiary 8-hydroxyquinoline-7- carboxamide derivatives and usage thereof
MX2015013240A (es) Método para proporcionar neuroprotección ocular.
MY164880A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids
MX346090B (es) Derivados de pirrolidina usados como inhibidores de catepsina.
GEP20135951B (en) Heterobicycle-substituted azolyl-benzene fungicide
IN2014DN03245A (enExample)